Latest research on Daptomycin

Daptomycin is a lipopeptide antibiotic that kills susceptible gram positive bacteria by disrupting their membrane potential. It is a naturally-occurring compound found in the soil bacterium Streptomyces roseosporus. Antibiotics are used in the treatment of infections caused by bacteria. They work by killing bacteria or preventing their growth. Daptomycin will not work for colds, flu, or other virus infections. It was approved in September 2003 for the treatment of complicated skin and soft tissue infections. It has a safety profile similar to other agents commonly administered to treat gram-positive infections.

Daptomycin side effects

Consecutive adults who underwent 2-stage revision arthroplasty using local and systemic Daptomycin for the treatment of PJI caused by methicillin-resistant Staphylococcus species were included. [source, 2016]
Twenty-two (10 knees, 12 hips) had PJI caused by methicillin-resistant Staphylococcus species and underwent 2-stage revision arthroplasty, with Daptomycin used in PMMA bone cement and systemically (Table 1). [source, 2016]
To our knowledge, this study was the first case-series report of Daptomycin used in PMMA bone cement to treat PJI caused solely by methicillin-resistant Staphylococcus species. [source, 2016]
Rouse et al. found that 3 g Daptomycin (7.5 % w/w) did not decrease the tensile or compressive strength of PMMA bone cement and retained biologic activity after PMMA cement polymerization in an in vivo rat model [31]. [source, 2016]
According to an in vitro study, the mean percentage of Daptomycin elution increased with an increase in Daptomycin loading [2.5, 7.5, and 15.0 % w/w] in PMMA bone cement. [source, 2016]
In another study, severe side effects (one case of acute renal failure due to massive rhabdomyolysis, one of eosinophilic pneumonia and 2 cases of asymptomatic transient CPK level elevation) were also reported with Daptomycin at a dose of 6.6 mg/kg/day for an average of 44.9 days in the treatment of PJI [13]. [source, 2016]
We thought a shorter course of systemic use of Daptomycin would be advisable because the adverse events would be fewer and the infection control rates would not be compromised. [source, 2016]
Phenotypic changes related to the membrane, including increased fluidity and increased positive surface charge associated with FA content and phospholipid composition, have been observed in S. aureus exposed to Daptomycin (Jones et al., 2008) and Antimicrobial peptides (Nawrocki et al., 2014). [source, 2016]
Differences in the proportion of iso and anteiso FA have been observed in Methicillin sensitive and resistant S. aureus strains (Pinchuk et al., 1983) and a significant increase in the anteiso/iso FA ratio accompanied by a decrease in saturated FA was observed in a Daptomycin resistant strain when compared to the sensitive strain (Mishra et al., 2014). [source, 2016]
In fact, it has been shown that heterogeneous Vancomycin-Intermediate-S. aureus (hVISA) and Vancomycin-Intermediate-S. aureus (VISA) strains present in common an increased positive cell wall charge responsible for the repulsion of vancomycin (Cafiso et al., 2012), as well as S. aureus strains resistant to Daptomycin and vancomycin (Cui et al., 2010). [source, 2016]